Lymphopenia and DMTs for Relapsing Forms of MS

Neurology: Clinical Practice - United States
doi 10.1212/cpj.0000000000000567
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Lymphopenia and DMTs for Relapsing Forms of MS: Considerations for the Treating Neurologist

Neurology: Clinical Practice
Neurology
2019English

Ocrelizumab for Relapsing or Primary Progressive MS

Prescriber
Pharmacology
2018English

Endocarditis Following Ocrelizumab in Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2020English

Natalizumab for Relapsing-Remitting Ms in the Uk Top Cohort

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2014English

Acute Effects of Alemtuzumab Infusion in Patients With Active Relapsing-Remitting MS

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2016English

Pnd120 - Treatment Decisions About First-Line Disease-Modifying Treatments (Dmts) in Relapsing Remitting Multiple Sclerosis: A Systematic Review of Patient Needs and Preferences

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Mixed Treatment Comparison of Adverse Events for BG-12, Glatiramer, and Teriflunomide for the Treatment of Relapsing Forms of Multiple Sclerosis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Pnd72 - Cost-Minimization Analysis of Teriflunomide and Dimethyl Fumarate for Treatment of Relapsing-Remitting Forms of Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd13 - Real World Evidence (Rwe) on Impact of Age on Long-Term Persistence to Disease Modifying Therapies (Dmts) in Relapsing-Remitting Multiple Sclerosis (Rrms) in Australia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy